Verismo to Unveil First-in-Human KIR-CAR Data for SynKIR-110 and SynKIR-310 at AACR 2026

New updates have been reported about Verismo Therapeutics.

Verismo Therapeutics will showcase pivotal first-in-human and preclinical data for its multi-chain KIR-CAR platform at the AACR Annual Meeting 2026 in San Diego, marking a key validation point for its lead assets SynKIR-110 and SynKIR-310. Initial Phase 1 data from the STAR-101 trial of SynKIR-110 in advanced mesothelin-expressing solid tumors will be delivered in an oral late-breaking session, positioning Verismo’s solid tumor program for heightened clinical and partnering visibility.

In parallel, Verismo will present preclinical and early Phase 1 results from the CELESTIAL-301 study of SynKIR-310 in relapsed or refractory B cell non-Hodgkin lymphomas, with data indicating superior performance versus second-generation CD3-based CAR T constructs in xenograft models and signs of early clinical activity. A separate late-breaking poster will detail EGFR-targeted KIR-CAR T preclinical data in glioblastoma developed with University of Pennsylvania collaborators, underscoring the platform’s potential breadth across solid and hematologic malignancies.

The company’s KIR-CAR architecture departs from conventional single-chain CAR T designs by using NK cell-derived KIR and DAP12 split-signaling independent of CD3, aiming to mitigate tonic signaling, reduce T cell exhaustion, and extend functional persistence in hostile tumor microenvironments. Verismo, a subsidiary of HLB Innovation, is currently the only developer of this multi-chain KIR-CAR approach, with both SynKIR-110 (NCT05568680) and SynKIR-310 (NCT06544265) in Phase 1 trials targeting high unmet-need solid tumors and B cell malignancies.

Chief Scientific Officer and COO Laura A. Johnson framed the AACR presentations as a transition point from preclinical proof of concept to human clinical readouts, which will be critical for future regulatory strategy, capital formation, and potential strategic collaborations. The University of Pennsylvania has licensed relevant intellectual property to Verismo and may receive future financial benefits, highlighting an embedded academic–industry linkage that could support ongoing pipeline expansion. While detailed efficacy and safety outcomes have not yet been disclosed, the combination of first-in-human data, comparative preclinical performance, and expansion into glioblastoma sets up multiple near- and medium-term catalysts for Verismo’s platform differentiation and potential value inflection.